No formal FDA breakthrough or fast-track designation for ibogaine is announced this quarter; any admin statement will carry an explicit cardiac safety caveat.

The FDA (the US drug regulator) has special labels it can give promising medicines to speed up their review — but ibogaine won't get one this quarter. Ibogaine can cause dangerous changes to heart rhythm, and any serious regulatory agency has to put safety warnings front and center before talking about approval timelines. Political messaging from the White House doesn't override that process.

MAHA framing is political theater. Ibogaine's QT-prolongation risk forces any credible regulator to lead with safety language, not approval timelines.